BOULDER, Colo. --(BUSINESS WIRE)--Dec. 19, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina , Blue Cross Blue

BOULDER, Colo. --(BUSINESS WIRE)--Dec. 16, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy , Jr. to the Company’s Board of Directors (Board) and Audit Committee of

BOULDER, Colo. --(BUSINESS WIRE)--Dec. 12, 2022-- Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the Company was named the leading Proteomics Solutions Company in the U.S.

BOULDER, Colo. --(BUSINESS WIRE)--Nov. 21, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public of

BOULDER, Colo. --(BUSINESS WIRE)--Nov. 17, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15

BOULDER, Colo. --(BUSINESS WIRE)--Nov. 16, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting

$30 million initial funding $20 million in future revenue milestone-based funding Strengthens balance sheet and extends runway with five-year interest only period BOULDER, Colo. --(BUSINESS WIRE)--Nov. 16, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with

Data confirms the ability of the VeriStrat ® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimens BOULDER, Colo. --(BUSINESS WIRE)--Nov. 10, 2022-- Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in

Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic portfolio; Conference

BOULDER, Colo. --(BUSINESS WIRE)--Oct. 20, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the third quarter ended September 30, 2022 before the open of trading on